BlueRidge Life Sciences
Consultancy providing integrated scientific, regulatory, engineering, and commercialization services across pharmaceuticals, biologics, medical devices, chemicals, foods, and consumer products. Core capabilities include nonclinical safety and toxicology, clinical development and adaptive trial design, regulatory strategy and submission support, epidemiology and biostatistics, health economics and market-access planning, cold-chain engineering and shipping validation, exposure science, human-centered device design and human factors, and lifecycle program and risk management.
Industries
Nr. of Employees
medium (51-250)
BlueRidge Life Sciences
Westlake Village, California, United States, North America
Services
Nonclinical safety and toxicology consulting
Design and oversight of nonclinical toxicology programs, pathology interpretation, immunotoxicology and genetic toxicology support to enable regulatory submissions.
Regulatory strategy and submission support
Regulatory planning, authority interactions, submission preparation and strategic advice for pediatric, rare disease, device, and combination-product pathways; coordination of multi-jurisdictional filings.
Epidemiology, biostatistics, and RWE services
Study design, statistical analyses, RWD/RWE generation, and publication strategy to support evidence generation and regulatory documentation.
Cold-chain validation, transport simulation and shipping qualification
Cold-chain design, worst-case shipping simulations, transport simulation studies that concurrently simulate temperature excursions and mechanical hazards, transport validation study design, operational and performance qualification, and data analysis for temperature-sensitive therapeutics aligned to regulatory expectations for filings.
Combination product and device consulting (DHF, human factors, user-needs mapping)
User needs analysis and validated prioritization, human factors/usability engineering, Design History File preparation, platform DHF development, and regulatory strategy for combination products and standalone devices.
HEOR, market-access and commercialization support
Evidence strategy, health economic modeling, market access assessments, pricing and reimbursement strategy, and preparation of payer and HTA communications to support product launch.
Nonclinical safety and toxicology consulting
Design and oversight of nonclinical toxicology programs, pathology interpretation, immunotoxicology and genetic toxicology support to enable regulatory submissions.
Regulatory strategy and submission support
Regulatory planning, authority interactions, submission preparation and strategic advice for pediatric, rare disease, device, and combination-product pathways; coordination of multi-jurisdictional filings.
Epidemiology, biostatistics, and RWE services
Study design, statistical analyses, RWD/RWE generation, and publication strategy to support evidence generation and regulatory documentation.
Cold-chain validation, transport simulation and shipping qualification
Cold-chain design, worst-case shipping simulations, transport simulation studies that concurrently simulate temperature excursions and mechanical hazards, transport validation study design, operational and performance qualification, and data analysis for temperature-sensitive therapeutics aligned to regulatory expectations for filings.
Combination product and device consulting (DHF, human factors, user-needs mapping)
User needs analysis and validated prioritization, human factors/usability engineering, Design History File preparation, platform DHF development, and regulatory strategy for combination products and standalone devices.
HEOR, market-access and commercialization support
Evidence strategy, health economic modeling, market access assessments, pricing and reimbursement strategy, and preparation of payer and HTA communications to support product launch.
Expertise Areas
- Clinical trial management and adaptive trial design
- Nonclinical toxicology and pathology
- Regulatory strategy and global submission coordination (drugs, devices, combination products)
- Epidemiology, biostatistics and real-world evidence generation
Key Technologies
- Physiologically based pharmacokinetic (PBPK) modeling
- Quantitative structure-activity relationship (QSAR) modeling
- In silico toxicology and predictive analytics
- Real-world data (RWD) / real-world evidence (RWE) analytics